CMS has issued guidance to Medicare Part D plans stating that anti-obesity medications (AOMs) that receive FDA approval for an additional medically accepted indication can be considered a Part D drug for that specific use.
Insurers may use prior authorization - or advance approval - to ensure that Wegovy is being used for a medically accepted indication.
[
add
]
[
|
|
...
]